HomeCompareBPMUF vs YUM

BPMUF vs YUM: Dividend Comparison 2026

BPMUF yields 2.82% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $83.1K in total portfolio value· pulled ahead in Year 2
10 years
BPMUF
BPMUF
● Live price
2.82%
Share price
$71.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.9K
Annual income
$337.79
Full BPMUF calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — BPMUF vs YUM

📍 YUM pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBPMUFYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BPMUF + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BPMUF pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BPMUF
Annual income on $10K today (after 15% tax)
$239.44/yr
After 10yr DRIP, annual income (after tax)
$287.12/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, YUM beats the other by $33,676.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BPMUF + YUM for your $10,000?

BPMUF: 50%YUM: 50%
100% YUM50/50100% BPMUF
Portfolio after 10yr
$65.5K
Annual income
$20,147.56/yr
Blended yield
30.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

BPMUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.1
Piotroski
8/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BPMUF buys
0
YUM buys
0
No recent congressional trades found for BPMUF or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBPMUFYUM
Forward yield2.82%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$23.9K$107.0K
Annual income after 10y$337.79$39,957.33
Total dividends collected$3.1K$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: BPMUF vs YUM ($10,000, DRIP)

YearBPMUF PortfolioBPMUF Income/yrYUM PortfolioYUM Income/yrGap
1$10,982$281.69$10,980$280.44+$2.00BPMUF
2← crossover$12,040$289.11$12,185$435.72$145.00YUM
3$13,178$296.22$13,722$684.14$544.00YUM
4$14,404$303.03$15,773$1,090.14$1.4KYUM
5$15,722$309.54$18,650$1,773.02$2.9KYUM
6$17,138$315.76$22,921$2,966.37$5.8KYUM
7$18,659$321.69$29,685$5,158.69$11.0KYUM
8$20,293$327.33$41,216$9,453.02$20.9KYUM
9$22,046$332.70$62,672$18,571.31$40.6KYUM
10$23,927$337.79$107,016$39,957.33$83.1KYUM

BPMUF vs YUM: Complete Analysis 2026

BPMUFStock

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.

Full BPMUF Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this BPMUF vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BPMUF vs SCHDBPMUF vs JEPIBPMUF vs OBPMUF vs KOBPMUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.